Showcases Stock ranks Forex

Brooklyn Immunotherapeutics Inc (BTX)
0.5172  -0.011 (-2.12%) 08-08 16:00
Open: 0.5399 Pre. Close: 0.5284
High: 0.5597 Low: 0.5
Volume: 1,108,404 Market Cap: 30M
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 0.561 - 0.564 0.564 - 0.566
Low: 0.494 - 0.497 0.497 - 0.499
Close: 0.515 - 0.52 0.52 - 0.525
Stock Technical Analysis
Target: Six months: 0.76
One year: 0.91
Support: Support1: 0.45
Support2: 0.37
Resistance: Resistance1: 0.65
Resistance2: 0.78
Pivot: 0.52
Moving Averages: MA(5): 0.51
MA(20): 0.54
MA(100): 0.95
MA(250): 4.20
MACD: MACD(12,26): -0.03
Signal(12,26,9): -0.03
%K %D: %K(14,3): 38.76
%D(3): 34.28
RSI: RSI(14): 41.94
52-Week: High: 13.63
Low: 0.45
Change(%): -95.2
Average Vol(K): 3-Month: 614
10-Days: 444
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

[ BTX ] has closed above bottom band by 46.3%. Bollinger Bands are 65.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 61 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Tue, 26 Jul 2022
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer - Yahoo Finance

Wed, 13 Jul 2022
Is Brooklyn Immunotherapeutics Inc (BTX) Stock a Smart Investment Wednesday? - InvestorsObserver

Fri, 17 Jun 2022
Brooklyn ImmunoTherapeutics receives non-compliance letter from Nasdaq (NASDAQ:BTX) - Seeking Alpha

Tue, 07 Jun 2022
Brooklyn ImmunoTherapeutics Announces Board Changes - GlobeNewswire

Tue, 31 May 2022
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting - GlobeNewswire

Fri, 27 May 2022
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q - GlobeNewswire

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 57.47
% Held by Insiders 31560000.00
% Held by Institutions 26.39
Shares Short (K) 3330
Shares Short Prior Month (K)
Stock Financials
EPS -29140000.000
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) -65.3
Return on Equity (ttm)
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.475
Qtrly Earnings Growth -2.83
Operating Cash Flow (M)
Levered Free Cash Flow (M) -25.49
Stock Valuation
PE Ratio
PEG Ratio -0.05
Price to Book value
Price to Sales
Price to Cash Flow
Stock Dividends
Dividend Yield
Dividend Growth 2230000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android